408 related articles for article (PubMed ID: 19361960)
1. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
2. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
3. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
4. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
5. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.
Pemán J; Cantón E; Quindós G; Eraso E; Alcoba J; Guinea J; Merino P; Ruiz-Pérez-de-Pipaon MT; Pérez-del-Molino L; Linares-Sicilia MJ; Marco F; García J; Roselló EM; Gómez-G-de-la-Pedrosa E; Borrell N; Porras A; Yagüe G;
J Antimicrob Chemother; 2012 May; 67(5):1181-7. PubMed ID: 22351683
[TBL] [Abstract][Full Text] [Related]
7. Recent experience with fungaemia: change in species distribution and azole resistance.
Chakrabarti A; Chatterjee SS; Rao KL; Zameer MM; Shivaprakash MR; Singhi S; Singh R; Varma SC
Scand J Infect Dis; 2009; 41(4):275-84. PubMed ID: 19229762
[TBL] [Abstract][Full Text] [Related]
8. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
Slavin MA; Sorrell TC; Marriott D; Thursky KA; Nguyen Q; Ellis DH; Morrissey CO; Chen SC;
J Antimicrob Chemother; 2010 May; 65(5):1042-51. PubMed ID: 20202987
[TBL] [Abstract][Full Text] [Related]
9. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V; Barnes AJ
J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
[TBL] [Abstract][Full Text] [Related]
10. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility.
Arendrup MC; Fuursted K; Gahrn-Hansen B; Schønheyder HC; Knudsen JD; Jensen IM; Bruun B; Christensen JJ; Johansen HK
Clin Microbiol Infect; 2008 May; 14(5):487-94. PubMed ID: 18294241
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.
Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U
J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683
[TBL] [Abstract][Full Text] [Related]
12. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
Oxman DA; Chow JK; Frendl G; Hadley S; Hershkovitz S; Ireland P; McDermott LA; Tsai K; Marty FM; Kontoyiannis DP; Golan Y
J Antimicrob Chemother; 2010 Jul; 65(7):1460-5. PubMed ID: 20430790
[TBL] [Abstract][Full Text] [Related]
13. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit.
Bassetti M; Ansaldi F; Nicolini L; Malfatto E; Molinari MP; Mussap M; Rebesco B; Bobbio Pallavicini F; Icardi G; Viscoli C
J Antimicrob Chemother; 2009 Sep; 64(3):625-9. PubMed ID: 19622536
[TBL] [Abstract][Full Text] [Related]
14. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
[TBL] [Abstract][Full Text] [Related]
15. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
Wilson AG; Micek ST; Ritchie DJ
Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
[TBL] [Abstract][Full Text] [Related]
16. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.
Yang YL; Li SY; Cheng HH; Lo HJ;
BMC Infect Dis; 2005 Nov; 5():99. PubMed ID: 16266438
[TBL] [Abstract][Full Text] [Related]
17. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan.
Chen TC; Chen YH; Tsai JJ; Peng CF; Lu PL; Chang K; Hsieh HC; Chen TP
J Microbiol Immunol Infect; 2005 Jun; 38(3):200-10. PubMed ID: 15986071
[TBL] [Abstract][Full Text] [Related]
18. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
[TBL] [Abstract][Full Text] [Related]
19. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood.
Tortorano AM; Rigoni AL; Biraghi E; Prigitano A; Viviani MA;
J Antimicrob Chemother; 2003 Oct; 52(4):679-82. PubMed ID: 12951345
[TBL] [Abstract][Full Text] [Related]
20. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
Cohen Y; Karoubi P; Adrie C; Gauzit R; Marsepoil T; Zarka D; Clec'h C
Crit Care Med; 2010 Mar; 38(3):826-30. PubMed ID: 20042858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]